The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Panic Disorder: Neurobiology And Mechanisms Of Cardiac Risk
Funder
National Health and Medical Research Council
Funding Amount
$456,657.00
Summary
Some people are subject to episodes of recurring, often inexplicable anxiety which are very unpleasant and accompanied by physical symptoms such as sweating, palpitations, tremor and a sensation of suffocation. Recurring attacks over a period of months, or years, forms the basis for the diagnostic of panic disorder. It has until recently been felt that although panic disorder was distressing and disabling, it did not constitute a risk of life. Sufferers often fear that they have heart disease, b ....Some people are subject to episodes of recurring, often inexplicable anxiety which are very unpleasant and accompanied by physical symptoms such as sweating, palpitations, tremor and a sensation of suffocation. Recurring attacks over a period of months, or years, forms the basis for the diagnostic of panic disorder. It has until recently been felt that although panic disorder was distressing and disabling, it did not constitute a risk of life. Sufferers often fear that they have heart disease, because of the nature of their symptoms, but have been reassured that this is not the case. Recent epidemiological studies, however, indicate that there is an increased risk in patients with panic disorder. Our hypotheses in this research project are as follow: That some specific genes predispose to the development of panic disorder - through actions on the nervous system and blood vessels That drug treatment (selective serotonin uptake blockers) and psychological treatment (cognitive behaviour therapy, CBT) reduce cardiac risk in panic disorder We will test these hypothesis using state of the art clinical scientific methods. Panic disorder has an important cardiological dimension which needs to be better understood for cardiac protection to be achieved in panic disorder patients.Read moreRead less
Panic Disorder: Neurobiology And Mechanisms Of Cardiac Risks
Funder
National Health and Medical Research Council
Funding Amount
$414,375.00
Summary
Some people are subject to episodes of recurring, often inexplicable anxiety which are very unpleasant and accompanied by physical symptoms such as sweating, palpitations, tremor and a sensation of suffocation. Recurring attacks over a period of months, or years, forms the basis for the diagnosis of panic disorder. It has until recently been felt that although panic disorder was distressing and disabling, it did not constitute a risk to life. Sufferers often fear that they have heart disease, be ....Some people are subject to episodes of recurring, often inexplicable anxiety which are very unpleasant and accompanied by physical symptoms such as sweating, palpitations, tremor and a sensation of suffocation. Recurring attacks over a period of months, or years, forms the basis for the diagnosis of panic disorder. It has until recently been felt that although panic disorder was distressing and disabling, it did not constitute a risk to life. Sufferers often fear that they have heart disease, because of the nature of their symptoms, but have been reassured that this is not the case. Recent epidemiological studies, however, indicate that there is an increased risk of heart risk in patients with panic disorder. Our hypotheses in this research are as follows: That panic disorder is characterised by increased release of the brain chemical messenger, serotonin, which is reversed by drug treatment with the most widely used class of drugs for this disorder, selective serotonin reuptake blockers That changes in an automatic stimulatory part of the nervous system, has primary importance in the disorder, in both genetically predisposing to panic disorder, and in mediating heart risk. That weight gain during therapy, a very common problem, is due to inhibition of brain serotonin release. We will test all these propositions using state of the art clinical scientific methods. Panic disorder has an important cardiological dimension which needs to be better understood for cardiac protection to be achieved in panic disorder patients. Our study of the mechanisms of cardiac risk should provide this. We will also provide very direct, valid measurements of chemical messenger release in the brain of panic disorder sufferers, using our unique methods. These should give a new understanding of the brain chemistry abnormalities of panic disorder, and the mechanism of action of the selective serotonin reuptake inhibitors.Read moreRead less
Antidepressants In Irritable Bowel: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$227,546.00
Summary
Irritable bowel syndrome is a common costly disorder in Australia; one in six Australians suffer with the condition. IBS can cause very substantial disability; some become housebound because of the need to have toilet facilities nearby. The currently available treatments for irritable bowel syndrome only provide at best partial relief or are completely ineffective. The literature suggests that individuals who suffer from an irritable bowel may benefit from the use of an antidepressant medication ....Irritable bowel syndrome is a common costly disorder in Australia; one in six Australians suffer with the condition. IBS can cause very substantial disability; some become housebound because of the need to have toilet facilities nearby. The currently available treatments for irritable bowel syndrome only provide at best partial relief or are completely ineffective. The literature suggests that individuals who suffer from an irritable bowel may benefit from the use of an antidepressant medication. Antidepressant medications have been shown to affect the function of the gastrointestinal system, in addition to relieving some of the psychological symptoms, such as depression and anxiety that are common in individuals with irritable bowel syndrome. To date, there have been no proper controlled trials of antidepressant medications in IBS, and there have been no studies at all into the new class of antidepressant medications, the selective serotonin reuptake inhibitors, in treating IBS. In this study we aim to investigate whether antidepressant medications are effective in treating irritable bowel syndrome by directly comparing a tricyclic (older class of antidepressant) with a selective serotonin reuptake inhibitor (new class of antidepressant) and with a placebo. All study participants will be closely monitored during the study. Patients will have their gastrointestinal symptoms, psychological symptoms, disability, quality of life and tolerance to the medication assessed. This will be the first comprehensive study of antidepressant medications assessed and the irritable bowel syndrome to be undertaken. The study will be conducted at the Nepean Hospital and the Royal North Shore Hospital; both of these centres have a well established treatment and research programs into the irritable bowel syndrome.Read moreRead less